{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:24:50Z","timestamp":1791829490163,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Objectives<\/jats:title>\n To provide a meta-analysis evaluating the predictive value of lymphocyte to monocyte ratio (LMR) in the efficacy and prognosis of bladder cancer patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Web of Science, Embase, Cochrane, and PubMed for literature searching up to November 2024 to identify research assessing the prognostic significance of LMR in bladder cancer patients. Outcomes included overall survival (OS), relapse-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS). Hazard ratios (HR) and 95% confidence intervals (CI) were used for data pooling of survival variables. In addition, for investigating potential heterogeneity sources and assessing the stability of the findings, sensitivity and subgroup analysis were performed. Review Manger 5.4 and STATA 15.1 were used to analyze.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Seventeen studies with 7,968 patients with bladder cancer included. The results indicated a notably shorter OS (HR: 1.56; 95% CI: 1.29, 1.89;\n P<\/jats:italic>\n &lt;0.00001), RFS (HR: 1.74; 95% CI: 1.27, 2.36;\n P<\/jats:italic>\n \u00a0=\u00a00.0005), PFS (HR: 2.04; 95% CI: 1.58, 2.64;\n P<\/jats:italic>\n &lt;0.00001) and CSS (HR: 1.24; 95% CI: 1.01, 1.52;\n P<\/jats:italic>\n \u00a0=\u00a00.04) in patients with low LMR compared to those with high LMR. Furthermore, subgroup analysis of OS found that study design, region, and age were the main factors affecting the correlation between LMR and OS.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n LMR can effectively predict the survival and recurrence risk of bladder cancer patients, helpingin the improvement of their prognosis. Future research should focus on large-scale, multicenter prospective cohort studies are still required in the future to evaluate the predictive value of LMR bladder cancer patients.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024618066<\/jats:uri>\n PROSPERO (CRD42024618066).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2025.1601040","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:37:49Z","timestamp":1759491469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of lymphocyte to monocyte ratio for the patients with bladder cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Qiang","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hankai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v136.5","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737159.2024.2428747","article-title":"Biomarkers of treatment response in bladder cancer","author":"Heard","year":"2024","journal-title":"Expert Rev Mol diagnostics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03694-z","article-title":"Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer","author":"Chen","year":"2024","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1481296","article-title":"Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1487676","article-title":"Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities","volume":"14","author":"Ma","year":"2024","journal-title":"Front Oncol"},{"key":"B8","article-title":"Unmet need in non-muscle-invasive bladder cancer failing bacillus calmette-gu\u00e9rin therapy: A systematic review and cost-effectiveness analyses from the international bladder cancer group","author":"D\u2019Andrea","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16081067","article-title":"Revitalizing bacillus calmette-gu\u00e9rin immunotherapy for bladder cancer: nanotechnology and bioengineering approaches","volume":"16","author":"Lv","year":"2024","journal-title":"Pharmaceutics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.31083\/j.fbl2908295","article-title":"Update on the mechanism of action of intravesical BCG therapy to treat non-muscle-invasive bladder cancer","volume":"29","author":"Abou Chakra","year":"2024","journal-title":"Front bioscience (Landmark edition)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12603","article-title":"Resolution of chronic inflammation and cancer","volume":"96","author":"Tezcan","year":"2024","journal-title":"Periodontology 2000"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.96338","article-title":"Bridging chronic inflammation and digestive cancer: the critical role of innate lymphoid cells in tumor microenvironments","volume":"20","author":"Shen","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/genes15091151","article-title":"The roles of proton-sensing G-protein-coupled receptors in inflammation and cancer","volume":"15","author":"Justus","year":"2024","journal-title":"Genes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.10.003","article-title":"A reappraisal of IL-9 in inflammation and cancer","author":"Bick","year":"2024","journal-title":"Mucosal Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104525","DOI":"10.1016\/j.critrevonc.2024.104525","article-title":"Associations between peripheral whole blood cell counts derived indexes and cancer prognosis: An umbrella review of meta-analyses of cohort studies","volume":"204","author":"Zhang","year":"2024","journal-title":"Crit Rev oncology\/hematology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12885-024-12349-9","article-title":"Prognostic value of the advanced lung cancer inflammation index in patients with gastric cancer after radical gastrectomy: a propensity-score matching cohort study and meta-analysis","volume":"24","author":"Pang","year":"2024","journal-title":"BMC cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00423-023-02786-8","article-title":"Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis","volume":"408","author":"Portale","year":"2023","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znac319","article-title":"Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis","volume":"109","author":"Savioli","year":"2022","journal-title":"Br J Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7593560","DOI":"10.1155\/2019\/7593560","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in bladder cancer undergoing radical cystectomy: A meta-analysis of 5638 individuals","volume":"2019","author":"Ma","year":"2019","journal-title":"Dis markers"},{"key":"B20","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Res ed)"},{"key":"B21","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011\n \n \n \n Wells\n G\n \n \n Shea\n B\n \n \n O\u2019Connell\n D\n \n \n Peterson\n J\n \n \n Welch\n V\n \n \n Losos\n M"},{"key":"B22","article-title":"Effect of red, processed, and white meat consumption on the risk of gastric cancer: an overall and dose-Response meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Nutrients"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v21:11","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Res ed)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655000","article-title":"Lymphocyte-to-monocyte ratio is the independent prognostic marker of progression in patients undergoing BCG-immunotherapy for bladder cancer","volume":"11","author":"Adamkiewicz","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2019.02.008","article-title":"The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer","volume":"29","author":"Albisinni","year":"2019","journal-title":"Progres en urologie: J l\u2019Association francaise d\u2019urologie la Societe francaise d\u2019urologie"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13743","article-title":"Comparison of De Ritis Ratio and other systemic inflammatory parameters for the prediction of prognosis of patients with transitional cell bladder cancer","volume":"75","author":"Batur","year":"2021","journal-title":"Int J Clin practice"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.06.006","article-title":"Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer","volume":"1","author":"Cantiello","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"B29","article-title":"Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy","volume":"115","author":"D\u2019Andrea","year":"2017","journal-title":"J Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10275","article-title":"Pretreatment PLR is preferable to NLR and LMR as a predictor in locally advanced and metastatic bladder cancer","volume":"3","author":"Karan","year":"2023","journal-title":"Cancer diagnosis prognosis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11100947","article-title":"Low preoperative lymphocyte-to-monocyte ratio is predictive of the 5-year recurrence of bladder tumor after transurethral resection","volume":"11","author":"Kim","year":"2021","journal-title":"J personalized Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.euros.2021.11.011","article-title":"Role of serum lymphocyte-derived biomarkers in nonmetastatic muscle-invasive bladder cancer patients treated with trimodal therapy","volume":"36","author":"Kool","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2015.56.11.749","article-title":"Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma","volume":"56","author":"Lee","year":"2015","journal-title":"Korean J urology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.937638","article-title":"Lymphocyte-to-monocyte ratio (LMR) during induction is a better predictor than preoperative LMR in patients receiving intravesical bacillus calmette -guerin for non-muscle-invasive bladder cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-1060","article-title":"A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with radical cystectomy for bladder cancer","volume":"9","author":"Shi","year":"2020","journal-title":"Trans Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9234067","DOI":"10.1155\/2020\/9234067","article-title":"Diagnostic and predictive values of inflammatory factors in pathology and survival of patients undergoing total cystectomy","volume":"2020","author":"Tang","year":"2020","journal-title":"Mediators inflammation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2019-0398","article-title":"Prognostic utility of the combination of pretreatment monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NMIBC after transurethral resection","volume":"13","author":"Wang","year":"2019","journal-title":"Biomarkers Med"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14118","article-title":"Prognostic value of preoperative inflammation markers in non-muscle invasive bladder cancer","volume":"75","author":"Y\u0131ld\u0131z","year":"2021","journal-title":"Int J Clin practice"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-4874-8","article-title":"Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy","volume":"37","author":"Yoshida","year":"2016","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biol Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3613-x","article-title":"Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biol Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.56434\/j.arch.esp.urol.20247702.22","article-title":"The prognostic value of the combination of the prognostic nutritional index and the lymphocyte: monocyte ratio for the prediction of patients with muscle-invasive bladder cancer","volume":"77","author":"Zhang","year":"2024","journal-title":"Archivos espanoles urologia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur urology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"155124","DOI":"10.1016\/j.prp.2024.155124","article-title":"Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic","volume":"254","author":"Alqurashi","year":"2024","journal-title":"Pathology Res practice"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403578","article-title":"Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy","volume":"15","author":"Tian","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1102778","article-title":"T lymphocyte cell: A pivotal player in lung cancer","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"crossref","first-page":"216805","DOI":"10.1016\/j.canlet.2024.216805","article-title":"The mast cell-T lymphocyte axis impacts cancer: Friend or foe","volume":"588","author":"Kannen","year":"2024","journal-title":"Cancer Lett"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2024.10339","article-title":"Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review","volume":"24","author":"Li","year":"2024","journal-title":"Biomolecules biomedicine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409356","article-title":"TIL therapy in lung cancer: current progress and perspectives","author":"Hu","year":"2024","journal-title":"Advanced Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03530-4","article-title":"Research advances on TIL therapy for colorectal cancer","volume":"26","author":"Jiang","year":"2024","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728222.2024.2427038","article-title":"Immunotherapies in breast cancer: harnessing the cancer immunity cycle","author":"Lok","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"B51","doi-asserted-by":"publisher","first-page":"217281","DOI":"10.1016\/j.canlet.2024.217281","article-title":"Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer","volume":"605","author":"Plaugher","year":"2024","journal-title":"Cancer letters"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13618","article-title":"From monocyte-derived macrophages to resident macrophages-how metabolism leads their way in cancer","volume":"18","author":"Ammarah","year":"2024","journal-title":"Mol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01013-0","article-title":"The chemokine monocyte chemoattractant protein-1\/CCL2 is a promoter of breast cancer metastasis","volume":"20","author":"Yoshimura","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.esmoop.2022.100776","article-title":"Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy","volume":"8","author":"Fendl","year":"2023","journal-title":"ESMO Open"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215460","article-title":"The monocyte, a maestro in the tumor microenvironment (TME) of breast cancer","volume":"14","author":"Amer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.12.015","article-title":"Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer","volume":"165","author":"Kawai","year":"2019","journal-title":"Surgery"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03333-y","article-title":"Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy","volume":"72","author":"Poirier","year":"2023","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br J cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1601040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:37:51Z","timestamp":1759491471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1601040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":58,"alternative-id":["10.3389\/fonc.2025.1601040"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1601040","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1601040"}}